Neuroplast is a clinical-stage biotechnology company developing Neuro-Cells®, a proprietary autologous stem cell platform and first-in-class therapy targeting neurodegeneration caused by trauma, disease, and ageing.

Founded in 2017, the company was established to advance this disruptive cell therapy initially for spinal cord injury–related neurodegeneration.

 

While neurodegenerative diseases vary widely in clinical presentation, they share common cellular degeneration pathways. Neuro-Cells® is designed to address these shared mechanisms, enabling potential application across multiple neurodegenerative indications.

 

Neuroplast holds two European Orphan Drug Designations for spinal cord injury and frontotemporal dementia, providing regulatory advantages including market exclusivity and accelerated development pathways. Increasing preclinical and clinical evidence supports the expansion of Neuro-Cells® into additional neurodegenerative indications.

 

With a scalable autologous platform, strong intellectual property position, and significant unmet medical need, Neuro-Cells® targets a multi-billion-euro global market and offers the potential to transform care for millions of patients for whom no disease-modifying treatments currently exist.